title: Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer.
abstract: Our ability to detect and directly target the oncogenic alterations responsible for tumor proliferation has contributed significantly to the management of lung cancer in the last decade. The therapeutic efficacy of molecularly targeted therapy is, however, mainly limited to patients harboring certain genetic mutations and is generally short-lived. Herein, we review primary and secondary drug resistance using the most well-studied of the molecularly targeted agents, the tyrosine kinase inhibitors targeting the epidermal growth factor (EGF) receptor, and the anaplastic lymphoma kinase (ALK) rearrangement, the current limitations of targeted therapies and their consequences on the management of patients with lung cancer.
authors.affiliation: Ottawa Hospital Research Institute , Ottawa, ON , Canada.
authors.forename: Johanna N
authors.initials: JN
authors.lastname: Spaans
authors.affiliation: Ottawa Hospital Research Institute , Ottawa, ON , Canada ; Ottawa Hospital Cancer Centre , Ottawa, ON , Canada ; Department of Medicine, University of Ottawa , Ottawa, ON , Canada.
authors.forename: Glenwood D
authors.initials: GD
authors.lastname: Goss
keywords: EGFR; acquired resistance; inhibition; molecular biology; primary resistance
references.citation: Clin Cancer Res. 2011 Oct 1;17(19):6298-303
references.pmid: 21856766
references.citation: Mol Cancer Res. 2007 Mar;5(3):203-20
references.pmid: 17374728
references.citation: Clin Cancer Res. 2013 Apr 15;19(8):2240-7
references.pmid: 23470965
references.citation: Anticancer Res. 2010 Jul;30(7):2513-7
references.pmid: 20682976
references.citation: J Clin Oncol. 2012 Feb 1;30(4):433-40
references.pmid: 22215752
references.citation: PLoS Med. 2007 Oct;4(10):1669-79; discussion 1680
references.pmid: 17973572
references.citation: N Engl J Med. 2009 Sep 3;361(10):947-57
references.pmid: 19692680
references.citation: J Thorac Oncol. 2012 Feb;7(2):419-26
references.pmid: 22237261
references.citation: J Clin Oncol. 2012 Sep 20;30(27):3337-44
references.pmid: 22753918
references.citation: Neoplasia. 2008 Mar;10(3):298-302
references.pmid: 18320074
references.citation: J Clin Oncol. 2008 Sep 10;26(26):4268-75
references.pmid: 18626007
references.citation: Sci Transl Med. 2011 Jul 6;3(90):90ra59
references.pmid: 21734175
references.citation: Lung Cancer. 2013 Mar;79(3):276-82
references.pmid: 23261231
references.citation: Lung Cancer. 2014 May;84(2):121-6
references.pmid: 24629636
references.citation: Eur J Cancer. 2002 May;38(8):1133-40
references.pmid: 12008203
references.citation: Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2127-33
references.pmid: 22773810
references.citation: Clin Cancer Res. 2011 Mar 1;17(5):1169-80
references.pmid: 21248300
references.citation: Clin Cancer Res. 2011 Mar 1;17(5):1160-8
references.pmid: 21233402
references.citation: Clin Cancer Res. 2006 Oct 1;12(19):5764-9
references.pmid: 17020982
references.citation: Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2166-71
references.pmid: 16609030
references.citation: J Clin Oncol. 2010 Jan 10;28(2):357-60
references.pmid: 19949011
references.citation: Lancet Oncol. 2011 Feb;12(2):175-80
references.pmid: 21277552
references.citation: N Engl J Med. 2002 Jan 10;346(2):92-8
references.pmid: 11784875
references.citation: N Engl J Med. 2011 Jul 28;365(4):379-80
references.pmid: 21793762
references.citation: J Thorac Oncol. 2011 Dec;6(12):2011-7
references.pmid: 22052230
references.citation: Chem Biol Drug Des. 2011 Dec;78(6):999-1005
references.pmid: 22034911
references.citation: BMC Cancer. 2011 Jan 01;11:1
references.pmid: 21194487
references.citation: Nat Genet. 2005 Dec;37(12):1315-6
references.pmid: 16258541
references.citation: J Clin Oncol. 2006 Nov 1;24(31):5034-42
references.pmid: 17075123
references.citation: J Clin Oncol. 2007 Oct 20;25(30):4743-50
references.pmid: 17909199
references.citation: J Clin Oncol. 2013 Mar 10;31(8):1070-80
references.pmid: 23401451
references.citation: J Clin Oncol. 2013 Sep 20;31(27):3327-34
references.pmid: 23816960
references.citation: J Clin Oncol. 2005 Apr 10;23(11):2544-55
references.pmid: 15753462
references.citation: Nat Rev Cancer. 2012 Jun 07;12(7):494-501
references.pmid: 22673150
references.citation: Lancet Oncol. 2011 Aug;12(8):735-42
references.pmid: 21783417
references.citation: Annu Rev Biochem. 1987;56:881-914
references.pmid: 3039909
references.citation: J Thorac Oncol. 2013 Sep;8(9):1136-41
references.pmid: 23887170
references.citation: Lancet Oncol. 2010 Feb;11(2):121-8
references.pmid: 20022809
references.citation: N Engl J Med. 2010 Oct 28;363(18):1734-9
references.pmid: 20979473
references.citation: Lancet Oncol. 2012 May;13(5):528-38
references.pmid: 22452896
references.citation: Lancet Oncol. 2014 Feb;15(2):213-22
references.pmid: 24439929
references.citation: Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7
references.pmid: 18093943
references.citation: Med Oncol. 2011 Jun;28(2):572-7
references.pmid: 20237869
references.citation: J Clin Oncol. 2008 Jul 20;26(21):3543-51
references.pmid: 18506025
references.citation: PLoS One. 2009 Oct 06;4(10):e7273
references.pmid: 19806209
references.citation: Cancer Discov. 2011 Sep;1(4):352-65
references.pmid: 22145099
references.citation: Clin Cancer Res. 2013 Aug 1;19(15):4273-81
references.pmid: 23729361
references.citation: Cancer. 2014 Apr 15;120(8):1145-54
references.pmid: 24501009
references.citation: Clin Cancer Res. 2014 Apr 1;20(7):2001-10
references.pmid: 24493829
references.citation: J Clin Oncol. 2012 Apr 1;30(10):1114-21
references.pmid: 22370318
references.citation: Pharmgenomics Pers Med. 2013 Apr 04;6:25-36
references.pmid: 23690695
references.citation: N Engl J Med. 2013 Jun 20;368(25):2385-94
references.pmid: 23724913
references.citation: Nature. 2007 Aug 2;448(7153):561-6
references.pmid: 17625570
references.citation: Cancer Res. 2009 Apr 15;69(8):3256-61
references.pmid: 19351834
references.citation: Nat Rev Cancer. 2013 Sep;13(9):663-73
references.pmid: 23949426
references.citation: Cancer Res. 2004 Dec 15;64(24):8919-23
references.pmid: 15604253
references.citation: Sci Transl Med. 2011 Mar 23;3(75):75ra26
references.pmid: 21430269
references.citation: J Thorac Oncol. 2012 Nov;7(11):1722-7
references.pmid: 23059777
references.citation: Cell. 2012 Nov 21;151(5):937-50
references.pmid: 23178117
references.citation: Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):914-26
references.pmid: 14967451
references.citation: Adv Med Sci. 2011;56(2):275-84
references.pmid: 22037177
references.citation: Lung Cancer. 2006 Nov;54(2):209-15
references.pmid: 16930767
references.citation: J Clin Oncol. 2012 Aug 20;30(24):3002-11
references.pmid: 22778317
references.citation: Cancer Discov. 2012 Oct;2(10):922-33
references.pmid: 22956644
references.citation: J Thorac Oncol. 2013 Mar;8(3):346-51
references.pmid: 23407558
references.citation: J Natl Cancer Inst. 2005 Mar 2;97(5):339-46
references.pmid: 15741570
references.citation: J Thorac Oncol. 2012 Oct;7(10):1583-93
references.pmid: 22982659
references.citation: Clin Cancer Res. 2010 Nov 15;16(22):5489-98
references.pmid: 21062933
references.citation: Lung Cancer. 2005 Mar;47(3):325-36
references.pmid: 15713516
references.citation: J Clin Oncol. 2011 Dec 1;29(34):4574-80
references.pmid: 22025157
references.citation: Lancet Oncol. 2012 Mar;13(3):239-46
references.pmid: 22285168
references.citation: Clin Cancer Res. 2000 Sep;6(9):3739-47
references.pmid: 10999768
references.citation: N Engl J Med. 2010 Oct 28;363(18):1693-703
references.pmid: 20979469